Monday, Oct 30
IVF 2017: Are We Ready to Use Paradigms that Predict and Personalize?
10:15 am – 10:55 am
Scott M. Nelson, M.D., Professor and Muirhead Chair of Obstetrics and Gynecology, University of Glasgow, UK
Mark Adams, Ph.D., Chief Information Officer, Celmatix Inc., New York
Presented by Ferring Pharmaceuticals
AMH Testing – Then and Now: Introducing the Roche Elecsys AMH Assay
3:15 pm – 3:55 pm
Today, more than ever, women are seeking fertility advice, as many are waiting longer in life to start their families. Anti-Müllerian Hormone has become one of the key markers for ovarian reserve based on the growing evidence of its utility. In the past, the available assays for AMH were manual, intended for Research Use Only and suffered in the area of performance- precision and reproducibility. New AMH assays show promise for eliminating interferences, improving precision and lot to lot consistency. Recently, the Roche Elecsys AMH assay became the first and only FDA cleared AMH assay on the market which not only provides excellent performance, but automates testing with results in as little as 18 minutes, making AMH testing accessible for in-house testing for most fertility clinics.
Emily Jungheim, MD, MSCI, Associate Professor, Reproductive Endocrinology and Infertility, Obstetrics and Gynecology, Washington University
Presented by Roche
Tuesday, Oct 31
The Fibroid Effect: The Impactful Consequences of Uterine Fibroids
10:15 am – 10:55 am
How are uterine fibroids impacting your patients? In a nationa lsurvey of 968 women aged 29 to 59 years
with uterine fibroids, 1 in 4 women reported being afraid their uterine fibroids will affect their ability to have a successful and healthy pregnancy1*. Learn more by attending Allergan’s EXPO Theater presentation.
* Question: I’m afraid fibroids will affect my ability to have a successful and healthy pregnancy.
Response options: strongly/somewhat agree, strongly/somewhat disagree, not applicable.
† 1 in 4 women responded strongly/somewhat agree (25%).
1 Borah BJ, Nicolson WK, Bradley L, Stewart EA. The impact of uterine leiomyomas: a national
survey of affected women. AM J Obstet Gynecol. 2013;209(4): 319.e1-319.e20.
Fady Sharara, M.D.,Medical Director, Virginia Center for Reproductive Medicine
Presented by Allergan
2017 ASRM Corporate Member Council Industry Session
12:30 pm – 1:25 pm
Join us for the 9th Annual CMC Industry Session in the ASRM Expo Theater. This dynamic Ted Talk style
session will feature two highly relevant topics impacting reproductive medicine and patient care. This
session is for both ASRM attendees and ASRM industry partners and exhibitors. The ASRM Corporate
Member Council represents a partnership between ASRM leadership and the Corporate Members
for creating and maintaining an open dialogue to better identify collaborative educational initiatives
which serve to enhance the practice of reproductive medicine.
Patient Retention: It’s No Just About Pregnancy Rates
Alice D. Domar, Ph.D.,
Executive Director, Domar Centers for Mind/Body Health, Associate Professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
Progressive Science in an Age of Regressive Policy
Sean Tipton, M.A.,
Chief Advocacy, Policy and Development Officer, American Society for Reproductive Medicine
Presented by the American Society for Reproductive Medicine
Virtual Reality Simulation in Healthcare Training
3:15 pm – 3:55 pm
VirtaMed is the world leader in high-fidelity virtual reality simulation for training of minimally invasive
diagnostic and therapeutic interventions in various medical disciplines. Together with ASRM
we have created the world’s most realistic Embryo Transfer simulator that is revolutionizing and
improving the way this procedure is taught. The ET Sim module si an extension of our existing
PelvicSim simulator that allows for teaching in hysteroscopy, IUD placement, and transabdominal
and transvaginal ultrasound. Join us for an overview of how high fidelity simulation is enhancing
surgeon training and increasing patient safety and an opportunity for a hands on demo session.
Rick Hoedt,Virtamed AG
Presented by Virtamed